Lodo Therapeutics Achieves Second Preclinical Milestone In Its Strategic Collaboration With Genentech

Lodo Therapeutics Corp. today announced it has achieved a second preclinical milestone in its multi-target strategic collaboration with Genentech, a member of the Roche Group. Lodo Therapeutics is using its proprietary genome mining and biosynthetic gene cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech.

Under the terms of the agreement, Lodo is eligible to receive research, development and commercialization payments based on achievement of certain predetermined milestones. In addition, Lodo received an undisclosed upfront payment and is eligible to receive royalties on sales of certain products resulting from the collaboration.

Dale Pfost, PhD, Chairman and CEO of Lodo Therapeutics Said: "Our collaboration with Genentech has now achieved a second preclinical milestone, and we anticipate additional milestones in the months ahead, Genentech has been an excellent partner as we have expanded the capabilities of our P4 discovery platform, and we look forward to furthering our mutually productive relationship."

Lodo's DNA-first approach identifies promising bioactive molecules directly from sequence data encoded in biosynthetic gene clusters (BGCs) in microbial DNA. By hacking into nature's BGCs, Lodo is leveraging billions of years of evolution-driven chemical diversity and biological relevance to identify novel drugs for hard-to-treat disease targets. Our P4 Platform leverages this data using next-generation sequencing, machine learning and computational biology to identify, characterize and prioritize lead candidates in silico. We use synthetic biology to boost production and enhance candidate molecules' pharmacologic properties, including their ability to engage challenging targets. Together, these integrated technologies have the potential to increase the productivity, scalability and efficiency of the drug discovery process by orders of magnitude. Lodo is currently directing the P4 Platform against five high value oncology targets that are considered undruggable and expects to add additional programs in other indications going forward.

Related Posts

Subscribe Our Newsletter